Under the COVID-19 pandemic, how is the development of the high-profile in vitro diagnostic industry? On June 10, taking YHLO as a classic example, the Finance Channel of China Central Television focused specifically on the topical subject of IVD industry development. The show reported the production and operation of YHLO, and its usage of intelligent pipeline products in medical institutions under COVID-19.

The report indicated that the capacity of the Chinese IVD market has reached 150 billion yuan in 2020. For the first time, the market share of Chinese-branded IVD products has exceeded that of imported brands due to the COVID-19 pandemic.

Relying on years of continuous improvement and innovation in the IVD industry, YHLO had rapidly developed a SARS-CoV-2 IgM and IgG antibody detection kit, and realized the entire process of independent R&D and manufacture once the pandemic broke out last year. Soon after, YHLO also launched SARS-CoV-2 antigen and neutralizing antibody detection series of diagnostic products. In that very year, those products have entered many countries since acquiring CE certification and getting on the List of China Chamber of Commerce for Import and Export of Medicines and Health Products, which has strongly assisted the fight against the pandemic all over the world.

“Last year, we achieved growth against the trend.” Michael Hu, chairman of YHLO, told the reporters. The company's export value of SARS-CoV-2 detection products in 2020 is fruitful. While supporting the domestic and international fight against the pandemic, YHLO has also jointly published about 190 academic papers using YHLO’s SARS-CoV-2 testing products with authoritative medical institutions in various countries.